stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Total debt
ADMA Biologics Inc's total debt at the end of fiscal 2025 was $76.0M, down 6.08% from $80.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $198.9M. Over the past ten years it has ranged from $14.3M (fiscal 2015) to $153.5M (fiscal 2022); the current reading is higher than 45% of that period. ADMA Biologics Inc ranks 58th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $76.0M | (6.08%) |
| FY2024 | $80.9M | (42.37%) |
| FY2023 | $140.4M | (8.57%) |
| FY2022 | $153.5M | 50.04% |
| FY2021 | $102.3M | 5.16% |
| FY2020 | $97.3M | 14.84% |
| FY2019 | $84.7M | 104.35% |
| FY2018 | $41.5M | 3.12% |
| FY2017 | $40.2M | 117.95% |
| FY2016 | $18.4M | 29.03% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $198.9M | (0.52%) |
| Mar 2026 | $199.9M | 163.17% |
| Dec 2025 | $76.0M | (4.41%) |
| Sep 2025 | $79.5M | (3.89%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| PHVS Pharvaris N.V. compare | $559.6K |
| IMNM Immunome, Inc. compare | $228.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement